Full archive
Pharmacogenomics
Week of 16 June 2026
8 articles
Geno'X Veille — genox-veille.fr
Key takeaways this week
- ►UGT1A1 — Multicenter real-world study: UGT1A1 genotype-guided irinotecan dosing significantly reduces severe toxicity and hospitalizations.
- ►CYP3A4 opioids — Co-prescribing macrolides with opioids (fentanyl, hydromorphone, oxycodone): real-world quantification of toxicity risk from CYP3A4 inhibition.
- ►DPYD/UGT1A1 — Variant-by-variant impact of genotype-guided dosing on fluoropyrimidine and irinotecan toxicity: from 43% to 16% severe toxicity.
Category:
Filters··Min. score
8 articles of 8
Sort
UGT1A1
PubMed★ Top pick
Real-World Impact of UGT1A1 Genotype-Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study.
Severe irinotecan toxicity in UGT1A1 poor metabolizers
0
/10
CPIC Level ADose recommendation
J Natl Compr Canc Netw 2026· JunRead
CYP3A4
PubMedOpioid Toxicity Following Concomitant Use of Macrolide Antibiotics with Fentanyl, Hydromorphone, or Oxycodone: A Population-Based Study.
Opioid toxicity from CYP3A4 drug-drug interaction
0
/10
Adverse reactionPhenoconversion
Clin Pharmacol Ther 2026· JunRead
DPYD
PubMedDPYD and UGT1A1 Genotype-Based Dosing for Fluoropyrimidines and Irinotecan Chemotherapy: Variant-Specific Impact on Treatment Intensity and Toxicity.
Fluoropyrimidine and irinotecan toxicity
0
/10
OncologyCPIC Level ADose recommendation
Int J Cancer 2026· JunRead
CYP2C19
PubMedCombinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases.
Cardiovascular diseases / pharmacogenomics
0
/10
DiabetesCPIC Level APreemptive genotyping
Pharmacogenomics 2026· JunRead
VKORC1
PubMedDerivation and Validation of a Genotype-Guided Warfarin Dosing Model in a Mixed Arab Population.
Warfarin anticoagulation / interindividual variability
0
/10
DiabetesCPIC Level ADose recommendation
Clin Appl Thromb Hemost 2026· JanRead
CYP3A4
PubMedHow Drug-Drug Interaction Studies Inform Drug Labeling: A Survey of US FDA-Approved New Molecular Entities from 1998 to 2022.
Drug-drug interactions / FDA labeling
0
/10
New interaction
Clin Pharmacol Ther 2026· JunRead
CYP3A5
PubMedPopulation pharmacokinetics of tacrolimus and CYP3A5-driven variability: implications for model-informed dose individualization in pediatric renal transplant recipients.
Tacrolimus PK variability in pediatric renal transplantation
0
/10
Dose recommendationRecurrent variant
BMC Pharmacol Toxicol 2026· JunRead
HLA-B
PubMedPharmacogenomics of antibacterial and antiviral therapies: Clinical actionability, evidence gaps, and future directions.
Pharmacogenomics of anti-infective therapies
0
/10
CPIC Level APreemptive genotyping
Pharmacol Rev 2026· AprRead
References and sources
- UGT1A1 — Severe irinotecan toxicity in UGT1A1 poor metabolizers. J Natl Compr Canc Netw 2026. PMID 42276133. Score 9/10. https://pubmed.ncbi.nlm.nih.gov/42276133/
- CYP3A4 — Opioid toxicity from CYP3A4 drug-drug interaction. Clin Pharmacol Ther 2026. PMID 41944476. Score 8/10. https://pubmed.ncbi.nlm.nih.gov/41944476/
- DPYD — Fluoropyrimidine and irinotecan toxicity. Int J Cancer 2026. PMID 42266018. Score 7/10. https://pubmed.ncbi.nlm.nih.gov/42266018/
- CYP2C19 — Cardiovascular diseases / pharmacogenomics. Pharmacogenomics 2026. PMID 42268291. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42268291/
- VKORC1 — Warfarin anticoagulation / interindividual variability. Clin Appl Thromb Hemost 2026. PMID 42262158. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42262158/
- CYP3A4 — Drug-drug interactions / FDA labeling. Clin Pharmacol Ther 2026. PMID 42257440. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42257440/
- CYP3A5 — Tacrolimus PK variability in pediatric renal transplantation. BMC Pharmacol Toxicol 2026. PMID 42288811. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42288811/
- HLA-B — Pharmacogenomics of anti-infective therapies. Pharmacol Rev 2026. PMID 42296571. Score 6/10. https://pubmed.ncbi.nlm.nih.gov/42296571/